Replies to post #544609 on NorthWest Biotherapeutics Inc (NWBO)

[hoffmann6383]

The first sentence conflicts with known facts. I didn't read further.

[exwannabe]

Very likely rGBM OS endpoint was defined before unblinding but it was certainly done AFTER the trial was complete -- a trial that was a NAIVE GBM trial

You are correct. The protocol change was submitted in 9/2022. The trial completion data is unknown but would have to be well before data lock and if NWBO is to be believed was prior to 6/2022.

The more important point is that despite being blinded, they knew the results of the IA (as a fact) and other analysis (as an opinion, but I would be very certain). And changing endpoints after one knows the original failed is a huge issue.